NCT00781794撤回1 期
A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of Single Oral Doses of NSA-789 on Auditory P50 Suppression in Nonsmoking Patients With Stabilized Schizophrenia
Wyeth is now a wholly owned subsidiary of Pfizer0 个研究点开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- 主要终点
- electroencephalogram
研究概览
简要总结
The purpose of this study is to evaluate the effect of single doses of NSA-789 on the P50 component of the auditory evoked potentials and to assess the safety, tolerability and the concentration of NSA-789 in the blood, in nonsmoking patients with schizophrenia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
1
Experimental
Dose 1
干预措施: NSA-789 at 2 different doses (Drug)
2
Experimental
Dose 2
干预措施: NSA-789 at 2 different doses (Drug)
3
Placebo Comparator
干预措施: NSA-789 at 2 different doses (Drug)
结局指标
主要结局
electroencephalogram
时间窗: 8 weeks
次要结局
- blood sample(8 weeks)
研究者
相似试验
Unknown
2 期
A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia PatientsSchizophreniaNCT00725855Memory Pharmaceuticals12
已完成
1 期
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.NeoplasmsNCT00091585Sunesis Pharmaceuticals
已完成
1 期
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid TumorsNeoplasmsNCT00094159Sunesis Pharmaceuticals
已完成
1 期
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy VolunteersDepressive Disorder and Anxiety DisordersNCT00513565GlaxoSmithKline22
终止
2 期
A Study to Evaluate ASP0367 in Participants With Primary Mitochondrial MyopathyPrimary Mitochondrial MyopathyNCT04641962Astellas Pharma Inc34